What is the ERA® (Endometrial Receptivity Analysis) test?
ERA®test, developed and patented by Igenomix (PCT/ ES2009/000386), is a test designed to evaluate endometrial receptivity.
ERA® is the first diagnostic test that determines each woman’s unique personalized embryo transfer timing, therefore synchronizing the embryo transfer with the individualized window of implantation.
What is the procedure?
1 – Learning from more than 200,000 women, the highest number of cases in the market
With over 200.000 women worldwide having undergone the test, the ERA predictor algorithm is based on artificial intelligence, allowing for continual refinements, and learning from those women who have successfully had pregnacies following the ERA recommendation.
ERA is the test with the most data published about clinically monitoring patients during pregnancy, enabling us to make a personalised embryo transfer recommendation with the highest accuracy.
2 – ERA is the endometrial receptivity test powered by most scientific background in the market
16 external publications supporting ERA and 6 internal with convincing clinical outcome.
Since it was developed and patented in 2009, both the Igenomix research team and independent clinics have written numerous publications showing the results of carrying out a personalised embryo transfer using the ERA.
The first endometrial receptivity test with UNE-EN ISO 15189 accreditation.
3 – The highest published clinical rates compared to any other test in the market
In the recurrent implantation failure (RIF) population, patients who underwent a personalized embryo transfer (pET) guided by ERA had significantly increased clinical outcomes versus those patients who did not undergo a pET guided by ERA. (Jia et al., 2022).
ERA is the endometrial receptivity test with the highest published clinical rates for patients with RIF. (Jia et al., 2022 vs Ohara et al., 2022)
RIF patients who undergo a pET guided by ERA found to have similar outcomes to those achieved by good prognosis patients. (Liu et al., 2022).
4 – Clinical support all the way. The largest Scientific community by your side
Igenomix maintains the strongest scientific team in the market, consisting of 15 global Scientific Advisors, dedicated endometrial specialists, and in-house clinicians to support you all the way.
5 – The originals and the first to approach endometrial health with a 360 view.
More than 65.000 EndomeTRIO (ERA, EMMA, and ALICE) samples analyzed in 5 years. Combined over 26 publications supporting our endometrial tests.
The endometrium is important: an imbalance in the endometrial flora caused by a low level of Lactobacillus and the presence of some pathogens is linked to worse reproductive results. (Moreno et al, AJOG 2016).
The presence of pathogenic bacteria in the endometrium can cause chronic endometritis, a silent illness suffered by 30% of women with infertility problems.(Cicinelli et al, Reprod Sci 2014).
By carrying out the EMMA and ALICE tests in addition to the ERA, we can discount or solve important causes of implantation failure and recurrent miscarriage based on just one sample of the endometrium.
Why use ERA® test?
ERA maximizes your patient’s chances of pregnancy.
This molecular diagnostic tool uses NGS to analyze the expression level of 248 genes related to the status of endometrial receptivity.
ERA is backed by ERA is backed by 25 publications; 16 from Igenomix and 9 external publications.
Proprietary algorithm based on machine learning that minimizes the need for second biopsy (90% of cases).
Allows clinicians to identify transition phases with 12 hours shifts.
Who should use ERA® Endometrial Receptivity Analysis test?
ERA test is indicated for patients with implantation failure of endometrial origin.
When is the second endometrial biopsy needed?
90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:
Patients with a “Pre-receptive” result needing 2 more days with progesterone.
*Simón et al., In vitro fertilization with personalized blastocyst transfer versus frozen or fresh blastocyst transfer: a multicenter, randomized clinical trial. Fertility and Sterility, 2019; 112. e56-e57. 10.1016/j.fertnstert.2019.07.273.
** Ruiz-Alonso et al., The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. Fertility and Sterility, 2013;100(3):818-24. 10.1016/j.fertnstert.2013.05.004.
We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility doctors worldwide we investigate human reproduction to change the lives of couples who are trying to conceive.
A new dimension of endometrial health to improve your reproductive prognosis
Evaluates the endometrium at the microbiological level